Ozempic vs Wegovy (2026): Same Drug, $1,028 vs $1,349 List, Here's Which You Need

Updated August 14, 2026: Ozempic and Wegovy are both semaglutide from Novo Nordisk. Ozempic is FDA-approved for type 2 diabetes at a max dose of 2mg/week and costs $1,027.51/month at list price. Wegovy is FDA-approved for weight management at a max dose of 2.4mg/week (or 7.2mg with Wegovy HD) and costs about $1,349/month at list price. NovoCare lists both pens at $199/month for the first two low-dose fills; Wegovy then costs $349/month at standard strengths ($399 HD), while Ozempic costs $349/month at 0.25-1mg or $499/month at 2mg. Pills start at $149/month and remain dose-dependent. Eligible commercially insured patients may pay as little as $25/month with a savings card. Eligible Medicare patients can get Wegovy at $50/month through the Medicare GLP-1 Bridge program. A telehealth alternative is Sprout Health at $199 for the first month (then $249/month), which offers both brand and compounded semaglutide with a dedicated care coordinator. If you have type 2 diabetes, Ozempic is usually the on-label product. If you have obesity without diabetes, Wegovy is the FDA-approved semaglutide brand for chronic weight management.

Quick answer by situation:

• •Have type 2 diabetes: Ask whether Ozempic is covered on your formulary; NovoCare lists its pen from $199/mo, prescription required and dose-dependent. Wegovy uses a different indication and dose range. For telehealth with both brand and compounded options, Sprout Health starts at $199 for the first month, then $249/mo.
• •No diabetes, want weight loss: Wegovy is the on-label semaglutide brand; Ozempic use for obesity would be off-label and coverage varies. NovoCare lists the Wegovy pen at $199/mo for the first two low-dose fills, then $349/mo at standard strengths ($399 for HD) and pill from $149/mo, prescription required and dose-dependent. Or compare advertised compounded semaglutide prices through Embody from $79 on a selected plan and Enhance MD from $49 first month, then verify the prescription and pharmacy pathway separately.
• •Want low-cost semaglutide: Compare Embody from $79 on a selected plan with Enhance MD from $49 first month, then $212/mo; see the compounded guide for legality.
• •Want to skip injections: The Wegovy pill produced 16.6% in OASIS and starts at $149/mo through NovoCare; Foundayo produced 12.4% in ATTAIN-1 and starts at $149/mo at 0.8 mg, rising by dose/refill timing. These were separate trials. Compare fasting, coverage, and the prescribed-dose total in the oral GLP-1 guide.

This guide breaks down every meaningful difference based on FDA labeling, the STEP-1 and SUSTAIN-6 clinical trials, and verified pricing from 54 telehealth providers. Compare all GLP-1 providers or take the 60-second match quiz.

Are Ozempic and Wegovy the Same Drug?

Yes, both are semaglutide from Novo Nordisk. The brands split by approval: Ozempic for Type 2 diabetes at up to 2 mg a week, Wegovy for weight management at 2.4 mg a week, or 7.2 mg for Wegovy HD.

Semaglutide is a GLP-1 receptor agonist, a synthetic version of a gut hormone that reduces appetite, slows gastric emptying, and improves blood sugar regulation. Novo Nordisk developed it first for diabetes under the brand name Ozempic, which received FDA approval in December 2017. When clinical trials showed significant weight loss as a side effect, Novo Nordisk ran a separate set of trials (the STEP program) at a higher dose and received a second FDA approval for weight management in June 2021 under the brand name Wegovy.

This two-brand strategy is common in pharma. The same molecule gets tested at different doses for different conditions and sold under different names with different pricing. It's the reason so much confusion exists, patients hear about "Ozempic for weight loss" in the media but their doctor prescribes Wegovy, or vice versa. Both work for weight loss, but the regulatory and practical differences are real and affect your wallet, your insurance coverage, and your dosing options.

What Are Ozempic and Wegovy FDA Approved For?

Ozempic is approved for glycemic control in adults with Type 2 diabetes, Wegovy for chronic weight management in adults with a BMI of 30 or greater, or 27 or greater with a weight-related comorbidity. Ozempic added a kidney disease indication in January 2025, Wegovy cardiovascular risk reduction in March 2024.

This is the most important practical distinction. The FDA approval determines how your doctor can prescribe each drug, how insurance companies evaluate coverage, and what the manufacturer can legally market it for.

Ozempic is approved as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus. In January 2025, Ozempic also received an expanded indication to reduce the risk of kidney disease worsening in adults with T2D and chronic kidney disease. Available doses are 0.25 mg (starter), 0.5 mg, 1 mg, and 2 mg, all as weekly injections.

Wegovy is approved for chronic weight management in adults with a BMI of 30 or greater (obesity), or BMI of 27 or greater (overweight) with at least one weight-related comorbidity such as hypertension, Type 2 diabetes, or dyslipidemia. In March 2024, Wegovy received an additional indication for cardiovascular risk reduction based on the SELECT trial, making it the first obesity drug ever approved to reduce the risk of heart attacks, strokes, and cardiovascular death.

The cardiovascular indication matters more than many people realize. The SELECT trial showed that semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events (MACE) by 20% compared to placebo in over 17,600 adults with obesity and established cardiovascular disease but without diabetes. This means Wegovy can sometimes be prescribed and covered under cardiovascular benefit categories even when weight loss coverage is denied, a pathway that simply doesn't exist for Ozempic in patients without diabetes.

How Do Ozempic and Wegovy Doses Compare?

Both medications use the same dose-escalation approach, start low, increase gradually every 4 weeks to minimize gastrointestinal side effects. But the available doses and maximum ceilings are different.

The escalation schedules look similar at the beginning, both start at 0.25 mg and increase to 0.5 mg after 4 weeks. The paths diverge from there. Ozempic tops out at 2 mg per week, which many doctors prescribe as the maximum therapeutic dose for diabetes management. Wegovy continues past that to 2.4 mg as the standard maintenance dose.

In March 2026, the FDA approved Wegovy HD (semaglutide 7.2 mg), a higher-dose injection that triples the standard Wegovy dose. In the STEP UP trial, the 7.2 mg dose produced 20.7% mean body weight loss compared to 17.5% with the standard 2.4 mg dose. Approximately 31% of patients on the 7.2 mg dose achieved 25% or greater weight loss. Wegovy HD is expected to be available in US pharmacies in April 2026.

For oral semaglutide, Wegovy is available as a daily 25 mg tablet approved in December 2025 for weight management. NovoCare now also lists an Ozempic pill from $149/month, prescription required and dose-dependent; Ozempic remains the diabetes-indicated brand rather than the on-label weight-management pill. Rybelsus (oral semaglutide 7 mg or 14 mg) is a separate diabetes brand. Product name, dose, and indication still matter even when the active ingredient overlaps.

Clinical Trial Results: Weight Loss Head to Head

Since Ozempic and Wegovy are the same molecule at different doses, there's no head-to-head trial comparing them directly. But we can piece together a clear picture from the published data across their respective trial programs, the SUSTAIN trials for Ozempic and the STEP trials for Wegovy.

The numbers tell a clear story. At Ozempic's typical diabetes doses (0.5-1 mg), patients in the SUSTAIN trials lost roughly 4-7% of body weight, meaningful for diabetes management, but modest for obesity treatment. At Wegovy's standard dose of 2.4 mg, the STEP 1 trial showed 14.9% mean weight loss in non-diabetic adults. And at the new Wegovy HD dose of 7.2 mg, the STEP UP trial showed 20.7%, now comparable to Zepbound's best results. For a month-by-month breakdown of what Wegovy patients typically experience on this trajectory, see our semaglutide before and after weight loss timeline.

There's an important caveat here: the SUSTAIN trials enrolled patients with Type 2 diabetes, while the STEP trials enrolled patients with obesity but without diabetes. People with Type 2 diabetes typically lose less weight on GLP-1 medications than people without diabetes, partly because insulin resistance affects the metabolic response. So the comparison isn't perfectly apples-to-apples. Still, the dose-response relationship is consistent, more semaglutide generally produces more weight loss, and Wegovy's higher dose ceiling is a genuine advantage for weight management.

The SELECT Trial: Wegovy's Cardiovascular Advantage

The SELECT trial is the single biggest differentiator between Ozempic and Wegovy from a clinical and insurance standpoint. Published in the New England Journal of Medicine in November 2023, it was a landmark study of 17,604 adults aged 45 and older with overweight or obesity and established cardiovascular disease, but without diabetes.

Over a mean follow-up of nearly 40 months, participants receiving semaglutide 2.4 mg weekly (the Wegovy dose) showed a 20% reduction in major adverse cardiovascular events (MACE), a composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke, compared to placebo. Breaking that down further: a 28% reduction in heart attacks, a 7% decrease in non-fatal strokes, and a 15% reduction in cardiovascular death. All-cause mortality was 19% lower in the semaglutide group.

These results led the FDA to approve Wegovy for cardiovascular risk reduction in March 2024, making it the first obesity treatment ever approved to reduce heart risk. Importantly, the cardiovascular benefits appeared early, within the first 3 months of treatment, before patients had achieved significant weight loss, suggesting the heart benefits may be partly independent of weight reduction.

Ozempic also has a cardiovascular indication, but only for patients with Type 2 diabetes and known heart disease (from the SUSTAIN 6 trial data). It does not have a cardiovascular indication for patients without diabetes. If you have obesity, cardiovascular risk factors, but no diabetes, only Wegovy has the FDA approval for cardiovascular risk reduction, and this distinction frequently determines insurance coverage.

What Are the Side Effects?

Since both drugs contain semaglutide, the side effect profiles are similar. The most common adverse reactions are gastrointestinal, especially during dose escalation. Higher doses tend to produce more side effects, which is relevant since Wegovy reaches a higher maximum dose than Ozempic.

The side effect rate difference is largely dose-driven. Ozempic's lower maximum dose (2 mg) generally means fewer and milder GI side effects than Wegovy at 2.4 mg or especially 7.2 mg. This is actually one reason some providers start patients on Ozempic and switch to Wegovy once they've demonstrated tolerability at lower doses, though this approach depends on insurance willingness to cover both.

Wegovy HD 7.2 mg introduced a new side effect signal: altered skin sensation, described as sensitivity, pain, or burning. This occurred more frequently at the 7.2 mg dose than at 2.4 mg and generally resolved on its own or with dose reduction. It was not a commonly reported issue at Ozempic's lower doses.

Pricing Comparison: August 2026

Pricing is where the "same drug, different brand" situation gets genuinely complicated. Novo Nordisk prices Ozempic and Wegovy differently, offers different savings programs, and insurance companies treat them differently based on the approved indication.

For patients with Type 2 diabetes, Ozempic is typically the more accessible option, it's on most diabetes formularies and covered under the diabetes benefit. For patients without diabetes who want semaglutide for weight loss, Wegovy is the intended product, though it faces more insurance hurdles since many plans still exclude weight management medications.

Novo Nordisk introduced subscription pricing for Wegovy in March 2026 through select telehealth providers including Ro, WeightWatchers, and LifeMD. A 12-month subscription brings the monthly cost to approximately $249, the lowest self-pay price available for brand-name injectable Wegovy. Ozempic does not currently have an equivalent subscription program.

If you're trying to figure out your actual out-of-pocket cost for either medication, our cost calculator can help you model different scenarios based on your insurance status, preferred medication, and available savings programs.

Does Insurance Cover Ozempic or Wegovy?

Which one is covered depends on your diagnosis. With Type 2 diabetes, Ozempic is on virtually every commercial and Medicare Part D formulary. Without diabetes, Wegovy coverage is far from guaranteed commercially, though Medicare Part D now covers it for weight loss at a flat $50/month copay.

Insurance is where the Ozempic vs Wegovy decision often gets made for you. The drugs' different FDA indications create entirely different coverage pathways, and understanding this can save you thousands of dollars or months of prior authorization battles.

If you have Type 2 diabetes: Ozempic is almost certainly the easier path. It's on the formulary of virtually every commercial and Medicare Part D plan for diabetes management. Your doctor prescribes it for diabetes, insurance covers it under the diabetes benefit, and you pay your normal copay (often $25-50/month with a manufacturer savings card). Weight loss happens as a welcome side effect, and nobody questions the prescription.

If you don't have diabetes and want weight loss: Wegovy is the intended option, but coverage is far from guaranteed. Many commercial insurers still exclude weight management medications from their formularies, or require extensive prior authorization. Typical requirements include documented BMI of 30+ (or 27+ with comorbidity), evidence of failed diet and exercise programs, and sometimes step therapy requiring you to try cheaper alternatives first.

The cardiovascular workaround: Wegovy's SELECT trial indication gives it a unique insurance pathway. If you have obesity plus established cardiovascular disease (prior heart attack, stroke, or peripheral arterial disease), your provider can prescribe Wegovy for cardiovascular risk reduction rather than weight loss. Some insurers cover this under the cardiovascular benefit even when they exclude weight loss drugs. This pathway does not exist for Ozempic in patients without diabetes.

• •Medicare Part D: Ozempic is covered for diabetes patients. Wegovy is now covered for weight loss as of July 1, 2026 under the Medicare GLP-1 Bridge program at a flat $50/month copay. A historic first. Neither was covered for weight loss before this program.
• •Commercial insurance: Check your specific formulary. Some plans cover Wegovy for weight management, some cover Ozempic for diabetes only, some cover both, and some cover neither for weight loss. The manufacturer savings cards (reducing your copay to as low as $25/month) only work with commercial insurance, not Medicare or Medicaid.
• •Medicaid: Coverage varies dramatically by state. Some state Medicaid programs cover Wegovy for weight management, while others exclude it entirely. Ozempic is generally covered for diabetes management across most state Medicaid programs.
• •Self-pay (no insurance): If you're paying cash, the price difference between Ozempic and Wegovy at equivalent doses is relatively small. Wegovy's subscription program through providers like Ro may offer the best value at $249/month for a 12-month plan.

If your insurance covers one but not the other, that's usually your answer. If both are covered, Wegovy is generally the better choice for weight management since it goes to a higher dose and has the cardiovascular indication as an additional clinical benefit.

Available Formulations in 2026

The formulation options have expanded significantly. Here's every semaglutide product currently available in the US:

If you want injectable semaglutide for diabetes, Ozempic is your option. If you want injectable semaglutide for weight loss, Wegovy (standard or HD) is your option. If you want a semaglutide pill for weight loss, oral Wegovy is the only FDA-approved choice. And if you want oral semaglutide for diabetes, Rybelsus fills that role.

The oral Wegovy tablet, approved in December 2025, showed 16.6% mean weight loss in the OASIS 4 trial, with one-third of adherent participants achieving at least 20% weight loss. It must be taken on an empty stomach with a small amount of water, then you wait 30 minutes before eating or drinking anything else. This fasting requirement is the main downside compared to pills like Foundayo (orforglipron), which has no fasting requirement.

NovoCare now lists an Ozempic pill from $149/month as well as the pen from $199/month, with a prescription and dose-dependent pricing. Rybelsus remains a separate oral semaglutide diabetes brand at different doses, and oral Wegovy is the weight-management brand. Do not treat Ozempic, Rybelsus, and Wegovy tablets as interchangeable simply because each uses semaglutide.

Who Should Choose Ozempic

Ozempic is the better choice in specific circumstances. Here's when it makes more sense:

• •You have Type 2 diabetes, Ozempic is the FDA-approved option for glycemic control and carries cardiovascular and renal protection indications for T2D patients. Insurance coverage is far more straightforward. If you're also comparing Mounjaro (tirzepatide) for T2D, see our Mounjaro vs Ozempic head-to-head: SURMOUNT-5 data shows tirzepatide beats semaglutide for weight loss in T2D.
• •Your insurance covers Ozempic but not Wegovy, if your formulary includes Ozempic for diabetes but excludes weight management drugs, and your doctor can justify the prescription for glycemic control, this may be your best path to affordable semaglutide
• •You want to start at a lower cost while testing tolerability, if you have diabetes, Ozempic at lower doses with insurance coverage can help you determine how well you tolerate semaglutide before potentially switching to Wegovy for higher-dose weight management
• •Your doctor prescribes it off-label and you're OK with the 2 mg ceiling, some patients achieve satisfactory weight loss at the 1-2 mg range and don't need the higher doses available with Wegovy
• •You have Type 2 diabetes with chronic kidney disease, Ozempic's January 2025 CKD indication makes it the only semaglutide product specifically approved to reduce kidney disease progression in T2D patients

Who Should Choose Wegovy

Wegovy is the better choice for most weight management patients. Here's when it's the clear winner:

• •You want maximum weight loss, Wegovy goes to 2.4 mg standard or 7.2 mg with Wegovy HD, compared to Ozempic's 2 mg ceiling. Higher doses mean more weight loss on average. The STEP UP trial showed 20.7% weight loss at 7.2 mg
• •You don't have diabetes, Wegovy is FDA-approved for weight management regardless of diabetes status. Using the drug that's actually approved for your condition is the cleanest regulatory and insurance path
• •You have cardiovascular risk factors, Wegovy's SELECT trial indication for cardiovascular risk reduction provides both clinical benefit and an additional insurance coverage pathway that Ozempic doesn't offer for non-diabetic patients
• •You prefer a pill for on-label weight management, oral Wegovy is the semaglutide tablet approved for that indication. NovoCare also lists an Ozempic pill, but Ozempic remains diabetes-indicated rather than an equivalent weight-management product
• •You're on Medicare and qualify for the GLP-1 Bridge, as of July 1, 2026 (now live), Wegovy (but not Ozempic) is covered at $50/month for eligible Medicare Part D beneficiaries seeking weight loss treatment
• •You want access to Novo Nordisk's subscription pricing, the new $249-329/month subscription plans through telehealth providers are currently available for Wegovy, not Ozempic

Can You Switch Between Ozempic and Wegovy?

Yes, and it's relatively straightforward since they're the same molecule. Switching between Ozempic and Wegovy is common, and your doctor can typically transition you at the equivalent dose without a new titration period. For example, if you're stable on Ozempic 1 mg, you could switch to Wegovy 1 mg and then continue escalating to the higher Wegovy doses (1.7 mg, 2.4 mg, and beyond).

Common switching scenarios include:

• •Ozempic to Wegovy: Typically done when a patient with diabetes wants to pursue higher-dose semaglutide for weight management, or when Wegovy becomes covered by insurance. Match the current Ozempic dose and continue escalation on the Wegovy schedule
• •Wegovy to Ozempic: Sometimes done when Wegovy has supply issues or insurance stops covering it. The patient steps down to Ozempic's maximum 2 mg dose, which means accepting a lower dose ceiling
• •Injectable to oral: Patients switching from injectable Wegovy to oral Wegovy start at the 3 mg oral dose and escalate to 7 mg, 14 mg, and then 25 mg regardless of their prior injectable dose, the oral bioavailability is different and requires its own titration

Frequently Asked Questions

Is Ozempic or Wegovy better for weight loss?

Wegovy, because it reaches higher doses. At equivalent doses, they produce the same weight loss, it's the same molecule. But Wegovy's standard maintenance dose (2.4 mg) is 20% higher than Ozempic's maximum (2 mg), and the new Wegovy HD goes up to 7.2 mg. The STEP 1 trial showed 14.9% mean weight loss with Wegovy 2.4 mg, while the STEP UP trial showed 20.7% with Wegovy HD 7.2 mg. Ozempic's clinical trials for diabetes showed 4-7% weight loss at its approved doses.

Can I use Ozempic for weight loss if I don't have diabetes?

Yes, through off-label prescribing. Your doctor can prescribe Ozempic for weight loss even without a diabetes diagnosis. However, your insurance is unlikely to cover it for this use, and you'll be limited to Ozempic's maximum 2 mg dose rather than the higher doses available with Wegovy. Many providers will prescribe Wegovy instead since it's the drug actually approved for this purpose.

Do Ozempic and Wegovy have the same side effects?

Yes, because they contain the same active ingredient. The side effect profiles are essentially identical at equivalent doses. The primary difference is that Wegovy's higher maximum dose means patients at 2.4 mg or 7.2 mg may experience more intense GI side effects than those on Ozempic's maximum 2 mg. Wegovy HD 7.2 mg also introduced altered skin sensation as a new side effect not commonly seen at lower doses.

Why did Novo Nordisk create two brands for the same drug?

Regulatory and commercial reasons. The FDA requires separate clinical trials and approvals for each therapeutic indication. By filing Wegovy separately for obesity, Novo Nordisk could set different pricing, run obesity-specific trials (STEP program), and market directly to weight management patients and providers. It also allows insurance companies to cover each brand under different benefit categories (diabetes vs weight management), which affects formulary decisions and pricing negotiations.

Will Wegovy work if Ozempic didn't work for me?

If you didn't lose weight on Ozempic, Wegovy at a higher dose might produce better results, assuming your Ozempic dose was below 2.4 mg. If you were already on Ozempic 2 mg with minimal results, adding another 0.4 mg with standard Wegovy is unlikely to dramatically change things. However, Wegovy HD at 7.2 mg represents a substantially higher dose that may produce additional weight loss. It's also worth discussing alternative medications like Zepbound (tirzepatide), which works through a different dual-receptor mechanism and may produce results where semaglutide alone didn't.

Is there a generic semaglutide available?

Not yet. Both Ozempic and Wegovy are still under patent protection from Novo Nordisk. Compounded semaglutide has been available from some pharmacies, but the FDA has stated that semaglutide is no longer on the drug shortage list as of late 2024, which affects the legal basis for compounding. The compounded vs brand-name landscape is complex, see our detailed breakdown for the full picture. True generic semaglutide (FDA-approved bioequivalent) is not expected until Novo Nordisk's patents expire.

Our Bottom Line

Ozempic and Wegovy are the same drug at different doses with different labels. For most people considering semaglutide for weight loss, Wegovy is the more appropriate choice, it's FDA-approved for that purpose, reaches higher doses, has the cardiovascular risk reduction indication, offers an oral tablet option, and is now accessible through subscription pricing programs and the Medicare GLP-1 Bridge at $50/month as of July 1, 2026.

Ozempic makes more sense if you have Type 2 diabetes (where it's the standard-of-care GLP-1 with excellent insurance coverage), if your insurance covers Ozempic but not Wegovy, or if your doctor recommends it for off-label weight management at doses you're comfortable with.

The most important thing is getting on the right medication at the right dose with proper medical supervision, the brand name on the box matters less than the semaglutide molecule reaching your GLP-1 receptors every week. Talk to your provider about which option makes the most sense given your diagnosis, your insurance, and your treatment goals.

Not sure where to start? Our ranked list of GLP-1 telehealth providers compares 54 platforms on pricing, medication options, and clinical support. The match quiz can pair you with the right provider in under 2 minutes based on your insurance, budget, and medication preference. And the cost calculator lets you model exactly what you'd pay for Ozempic or Wegovy through different access pathways.